title: [Flagellate dermatitis after bleomycin chemotherapy in a patient with malignant germ cell tumor].
abstract: METHODS
  A 49-year-old patient with malignant germ cell tumor within the first cycle PEB (platinum [P], etoposid [E] and bleomycin [B]) presented with an itchy linear papular erythema with discrete vesicles. The rash had appeared three days ago i. e. four days after the second application of bleomycin.
  
  
  METHODS
  Visual diagnosis of a flagellate dermatitis.
  
  
  METHODS
  Primary treatment consisted of systemic antihistamines, local and systemic application of steroids. Bleomycin treatment was stopped and substituted by ifosfamide.
  
  
  CONCLUSIONS
  Flagellate dermatitis occurs with an incidence up to 66 % after bleomycin treatment. There is no association between bleomycin dose and incidence or severity of the lesions. Flagellate dermatitis is a self-limiting condition but hyperpigmentation may persist. Similar lesions may occur with bendamustine and docetaxel, the intake of insufficiently cooked shiitake mushrooms as well as in dermatomyositis and Still's syndrome.
authors.affiliation: Klinik für Hautkrankheiten, Universitätsklinikum Jena.
authors.forename: C
authors.initials: C
authors.lastname: Schummer
authors.affiliation: Klinik für Urologie, Universitätsklinikum Jena.
authors.forename: Y
authors.initials: Y
authors.lastname: Winkler
authors.affiliation: Klinik für Hautkrankheiten, Universitätsklinikum Jena.
authors.forename: J
authors.initials: J
authors.lastname: Tittelbach
authors.affiliation: Klinik für Urologie, Universitätsklinikum Jena.
authors.forename: M-O
authors.initials: MO
authors.lastname: Grimm
authors.affiliation: Klinik für Hautkrankheiten, Universitätsklinikum Jena.
authors.forename: P
authors.initials: P
authors.lastname: Elsner
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use; D003875:Drug Eruptions / Q000175:diagnosis*; D057915:Drug Substitution; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy* / Q000473:pathology; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000903:Antibiotics, Antineoplastic; D001761:Bleomycin; D005047:Etoposide; D011239:Prednisolone; D002945:Cisplatin; D007069:Ifosfamide